AGENT SKILL

clinical-research

Use when designing a prospective clinical study before submission — selecting and classifying endpoints (primary / key-secondary / exploratory, with surrogate-endpoint flagging), estimating sample size and power for two-arm designs (means / proportions / survival), or scoring a study plan for feasibility and a GO / GO-WITH-CONDITIONS / REDESIGN / NO-GO phase-gate decision. Every output is an ESTIMATE plus a named human owner (clinician / biostatistician / regulatory owner) — never clinical fact, never a finished protocol. Distinct from ra-qm-team, which handles the regulatory/QM submission (ISO 13485, EU MDR, FDA 510(k)/PMA/QSR), not the study design.

License 许可
MIT
最近更新
2026-10-10
Stars
★ 0
Forks
0

01 前言 Front Matter

name
clinical-research
tags
[ "research-ops", "clinical-research", "study-design", "endpoint", "sample-size", "power", "phase-gate", "biostatistics" ]
author
claude-code-skills
license
MIT
version
2.9.0
description
Use when designing a prospective clinical study before submission — selecting and classifying endpoints (primary / key-secondary / exploratory, with surrogate-endpoint flagging), estimating sample size and power for two-arm designs (means / proportions / survival), or scoring a study plan for feasibility and a GO / GO-WITH-CONDITIONS / REDESIGN / NO-GO phase-gate decision. Every output is an ESTIMATE plus a named human owner (clinician / biostatistician / regulatory owner) — never clinical fact, never a finished protocol. Distinct from ra-qm-team, which handles the regulatory/QM submission (ISO 13485, EU MDR, FDA 510(k)/PMA/QSR), not the study design.
compatible_tools
[ "claude-code", "codex-cli", "cursor", "antigravity", "opencode", "gemini-cli" ]

02 资源文件 10

03 SKILL.md 正文

clinical-research

Prospective clinical study DESIGN: endpoints, sample size / power, and phase-gate feasibility. Every output is an estimate with stated assumptions routed to a named human owner. This skill never gives clinical advice as fact and never substitutes for a biostatistician or regulatory affairs.

Purpose

R&D clinical teams, medical monitors, and biostatistics functions live at the moment between we-have-a-hypothesis and we-have-a-protocol-ready-for-submission. This skill structures three of the hardest design decisions:

Three deterministic tools:

  1. sample_size_estimator.py — Closed-form power / sample-size for two-arm means (Cohen's d), proportions (normal approximation), and survival (Schoenfeld events). Inflates for dropout. Prints an "ESTIMATE — confirm with a biostatistician" banner.
  2. endpoint_selector.py — Scores candidate endpoints across 5 weighted dimensions (clinical relevance, measurability, regulatory acceptance, sensitivity-to-change, burden) and classifies each as PRIMARY / KEY-SECONDARY / EXPLORATORY. Penalizes unvalidated surrogate endpoints.
  3. phase_gate_scorer.py — Scores a study plan 0-100 across recruitment feasibility, endpoint readiness, statistical power, operational complexity, and budget fit; returns GO / GO-WITH-CONDITIONS / REDESIGN / NO-GO plus the named owners who must sign.

When to use

Invoke this skill when:

  • You are choosing a primary endpoint and need to defend it against surrogate-endpoint scrutiny.
  • You need a defensible first sample-size estimate for a protocol synopsis.
  • A study plan needs a feasibility read before a phase-gate review.
  • You are pressure-testing whether the planned enrollment is achievable given the eligible population and sites.

Do NOT use this skill to: prepare a regulatory submission or clinical evaluation report (use ra-qm-team), find or position a grant (use research/grants), design a live product A/B experiment (use product-team/experiment-designer), or replace a biostatistician's final sample-size justification.

Workflow

  1. Draft the synopsis — Fill assets/protocol_synopsis_template.md (objectives, design, population, endpoints, statistical plan placeholder, owners-to-sign).
  2. Select the endpoint — Run endpoint_selector.py --input endpoints.json --profile {drug|device|biologic|diagnostic|digital-therapeutic}. Read the classification + surrogate flags. If >1 primary, plan multiplicity control.
  3. Estimate the sample size — Run sample_size_estimator.py --design {means|proportions|survival} .... Trace the effect/difference/HR to a published or anchor-based source; inflate for dropout.
  4. Score feasibility — Run phase_gate_scorer.py --input study.json --profile <same> --phase {1|2|3|4}. Read the verdict + blockers + named owners.
  5. Route for sign-off — Assemble the synopsis + estimates into the gate packet. The packet is a recommendation; a biostatistician, medical monitor, and regulatory owner sign.

Scripts

Script Purpose Profiles
scripts/sample_size_estimator.py Power / sample-size for means, proportions, survival n/a (design-driven)
scripts/endpoint_selector.py 5-dimension endpoint scoring + classification + surrogate flag drug, device, biologic, diagnostic, digital-therapeutic
scripts/phase_gate_scorer.py Feasibility 0-100 + GO/GO-WITH-CONDITIONS/REDESIGN/NO-GO + owners drug, device, biologic, diagnostic, digital-therapeutic

All three: stdlib-only, --help, --sample, --output {human,json}.

Onboarding & customization

Run the onboarding questionnaire once before you start — it captures your defaults and named owners so every tool in this skill is pre-configured. Customization is the point: the answers actually change tool behavior.

python3 scripts/onboard.py            # interactive (also: --defaults, --set key=value, --reset)
python3 scripts/onboard.py --show     # see the questions + current effective config

Answers are saved to ~/.config/research-ops/clinical-research.json (global) or ./.research-ops/clinical-research.json (--scope project) and are read automatically by config_loader.py. They set the default development-area profile, default alpha / power / dropout, and the named biostatistician / medical monitor / regulatory owner printed on outputs. CLI flags always override saved config; RESEARCH_OPS_NO_CONFIG=1 ignores it entirely.

The seven questions: development area · alpha · power · dropout · biostatistician · medical monitor · regulatory owner.

Optimize with autoresearch (opt-in)

This skill ships an isolated, opt-in bridge to engineering/autoresearch-agent. Only when you ask to "optimize" / "run a loop" does an autoresearch experiment iteratively improve a study plan against this skill's own feasibility score. scripts/ar_evaluator.py is the ground-truth evaluator; it prints feasibility_composite: <0-100> (higher is better).

/ar:setup --domain custom --name trial-feasibility \
  --target study.json \
  --eval "python3 ar_evaluator.py --target study.json" \
  --metric feasibility_composite --direction higher
/ar:loop custom/trial-feasibility

Isolated: no hard dependency — autoresearch runs only on demand, and the loop edits study.json, never the evaluator (locked ground truth).

References

  • references/study_design_canon.md — ICH E8(R1) general considerations; ICH E9 + E9(R1) estimand addendum; CONSORT 2010; SPIRIT 2013; FDA Multiple Endpoints guidance (2022).
  • references/endpoint_and_power.md — Cohen Statistical Power Analysis; Schoenfeld (1983) survival sample size; FDA Surrogate Endpoint Table / BEST glossary; FDA PRO guidance (2009); Chow, Shao & Wang Sample Size Calculations in Clinical Research.
  • references/trial_operations.md — ICH E6(R2/R3) GCP; TransCelerate risk-based monitoring; FDA RBM guidance; CTTI recruitment best practices; site-feasibility scoring literature.

Assumptions

  • Sample-size formulas use normal approximations with a built-in z-table. They are first-pass estimates; a biostatistician produces the final justification (and may use simulation, adaptive designs, or exact methods).
  • The endpoint scorer applies customary regulatory priors per development area via --profile. Company- or indication-specific precedent overrides the prior.
  • The phase-gate scorer bakes in a profile cost-per-patient benchmark; pass a real budget to override the default.
  • An unvalidated surrogate cannot anchor a PRIMARY endpoint — the scorer enforces this with a penalty.

Anti-patterns

  • Presenting a power estimate as fact. Every output is an estimate with a named owner who must sign.
  • Powering for a convenience effect size. The effect must trace to a published or anchor-based MCID, not to the n you can afford.
  • Anchoring a primary on an unvalidated surrogate. Surrogate endpoints need validation evidence for the indication.
  • Ignoring multiplicity. More than one primary endpoint requires pre-specified alpha allocation.
  • Skipping dropout inflation. Raw n undersizes the study; inflate by 1/(1 − dropout).

Distinct from

Sibling / neighbor Scope Difference
ra-qm-team ISO 13485 QMS, ISO 14971 risk, EU MDR tech docs + clinical evaluation, FDA 510(k)/PMA/De Novo/QSR submission That is the submission; clinical-research designs the study beforehand
research/grants NIH funding discovery + positioning That finds funding; this designs the trial
product-team/experiment-designer Live product A/B hypothesis + sample size That is a product experiment; this is a clinical trial
research-finance (sibling) R&D program budget + burn That funds the program; this scopes the study

Quick examples

python3 scripts/sample_size_estimator.py --sample
python3 scripts/sample_size_estimator.py --design proportions --p1 0.30 --p2 0.45 --dropout 0.15
python3 scripts/endpoint_selector.py --sample
python3 scripts/phase_gate_scorer.py --sample --output json

The sample correctly flags an unvalidated serum-cytokine surrogate (cannot be primary) and ranks PASI-75 as the PRIMARY endpoint; the phase-gate sample returns a verdict with a named owner chain.

Forcing-question library (Matt Pocock grill discipline)

Walked one at a time by /cs:grill-research-ops or the orchestrator. Recommended answer + canon citation per question. Never bundled.

  1. "Is your primary endpoint a clinical outcome or a surrogate — and if surrogate, is it on FDA's validated table?" Recommended: clinical outcome unless the surrogate is validated for this indication. Canon: FDA Surrogate Endpoint Table; BEST (Biomarkers, EndpointS, and other Tools) glossary.

  2. "What's the minimal clinically important difference you're powering for — and where did that number come from?" Recommended: a published or anchor-based MCID, cited; never a convenience effect size. Canon: ICH E9; Cohen Statistical Power Analysis.

  3. "What dropout rate are you assuming, and is the sample size inflated for it?" Recommended: inflate n by 1/(1 − dropout) using a justified rate. Canon: Chow, Shao & Wang; ICH E9(R1).

  4. "Single primary endpoint or multiple — and if multiple, what's the multiplicity control?" Recommended: pre-specify alpha allocation (hierarchical / Bonferroni). Canon: FDA Multiple Endpoints guidance (2022).

  5. "Who is the named biostatistician / medical monitor / regulatory owner signing this synopsis?" Recommended: name them now — this output is a recommendation, not a protocol. Canon: ICH E6(R2) GCP roles & responsibilities.

Walk depth-first. Lock 1-2 before opening 3-5. After all are answered, invoke endpoint_selector.py → sample_size_estimator.py → phase_gate_scorer.py.

04 同仓库更多 Skills

azhri1990
azhri1990/jarvis-mega-repo

syllabus

Generates a curated supplementary reading list from any course syllabus using Consensus academic search. Grill-me intake (syllabus input format + course audience + year range) plus a grouping forcing-options checkpoint before any search runs — so the reading list matches the course's level and recency need. Parses the syllabus to extract topics and learning outcomes, searches Consensus for recent peer-reviewed papers per topic, and produces a professionally formatted .docx with clickable Consensus links, plain-language summaries calibrated to audience level, and Bloom-higher-order discussion questions tied to course learning goals. Use when the user uploads a syllabus, course outline, or curriculum document and wants supplementary readings (e.g., 'create a reading list from this syllabus', 'find recent papers for my course') — even casual mentions with a syllabus attached should trigger this skill.

★ 0
azhri1990
azhri1990/jarvis-mega-repo

pulse

Multi-source recency research skill that takes the pulse of any topic across Reddit, Hacker News, the open web, and optionally X/Twitter within a configurable recent window (default 30 days). Forcing intake clarifies topic specificity, angle (trend/sentiment/problems/opportunities/comparison), time window, and platform scope before searching. Returns a synthesized briefing with citations, engagement metrics, and cross-platform pattern analysis. Use when the user requests multi-source recency intelligence on a topic (e.g., 'pulse on [topic]', 'what's happening with [topic]', 'what are people saying about [topic]', 'current conversation about [topic]', 'take the pulse of [topic]', 'trending: [topic]', 'find me info on [topic]'), and for competitor research, trend discovery, tool comparisons, and audience sentiment analysis.

★ 0
azhri1990
azhri1990/jarvis-mega-repo

patent

Patent prior-art and landscape intelligence skill — not generic patent help. Commits to one of five sub-use-cases via forcing intake (novelty search / freedom-to-operate / competitive landscape / acquisition diligence / litigation prior-art) before any search runs. Searches Google Patents, Espacenet, USPTO, and optionally Lens.org for citation-graph signals. Output is an editable Word document (.docx) with verdict, ranked closest art (claim-text extracted), CPC-class-aware landscape, family-resolved hits, geographic coverage, FTO flags where applicable, strategy recommendations, and full audit log. Use when the user asks for patent searching or analysis (e.g., 'prior art search for [invention]', 'freedom to operate analysis for [product]'). Produces search signal, not legal advice — always recommends consulting a patent attorney before filing or licensing decisions. Trademark, copyright, and trade-secret questions are out of scope.

★ 0
azhri1990
azhri1990/jarvis-mega-repo

notebooklm

Browser automation skill for controlling Google's NotebookLM. Use when the user wants anything done in NotebookLM (e.g., 'open NotebookLM', 'check my [name] notebook', 'ask my notebook about X', 'add [source] to NotebookLM', 'generate a Video Overview from my notebook', 'use NotebookLM Studio'). Handles reading and querying notebooks, adding sources (URLs, text, files, YouTube links, synthesized content), generating Studio outputs (Audio/Video Overviews, Mind Maps, Reports incl. Briefing Doc/Study Guide/FAQ, Flashcards, Quiz, slide decks, infographics — discover the exact set from the live Studio panel; the UI evolves fast), and creating new notebooks. Requires browser automation environment — fails gracefully when unavailable.

★ 0
azhri1990
azhri1990/jarvis-mega-repo

litreview

Academic literature orientation skill that searches papers via free keyless APIs (PubMed E-utilities + OpenAlex) by default — with the Consensus MCP as an optional enhancement lane when connected — builds a strategic search plan using PICO (default) or SPIDER / Decomposition / hybrid as fallbacks, and synthesizes findings into a formatted Word (.docx) research guide. Grill-me intake (research question specificity + framework hint + tentative depth) before the recon search; a second forcing checkpoint after Phase 2 confirms framework + sub-areas + depth before searches consume budget. Configurable depth (5/10/20 queries) controls coverage vs. speed. Output is a 'launching pad' — an orientation guide that lets a researcher dive in confidently, not a finished review. Use when the user starts literature-oriented research (e.g., 'litreview on [topic]', 'literature review on [topic]', 'I'm starting a literature review on X', 'I'm writing a paper on X', 'help me research X', 'I'm doing research on X', 'can you help me research X'). Do NOT use for single one-off paper searches wanting a quick list — that's a plain PubMed/OpenAlex (or Consensus) query.

★ 0
azhri1990
azhri1990/jarvis-mega-repo

grants

NIH grant research skill for clinical researchers. Grill-me intake (research idea + career stage + preliminary data + environment + submission posture + known institute targets) locks down the funding strategy before any search runs. Runs a 5-facet Consensus positioning analysis (with draft Significance/Innovation language), maps the research to the right NIH institutes and study sections via RePORTER, finds NOSIs and funded overlap, and produces an editable Word document (.docx) with budget/scope-aware mechanism recommendations, submission timelines, and a mandatory program officer recommendation. Use when the user asks about research funding or makes any grant-related request (e.g., 'grants for [topic]', 'find grants for my research idea', 'what grants match my research', 'help me find NIH funding', 'grant opportunities for my research'). NIH-only scope — non-NIH funders (PCORI, DOD CDMRP, VA, foundations) are out of scope and flagged at intake.

★ 0